Daiichi Sankyo Company Ltd. (Daiichi Sankyo), a global pharmaceutical company, has signed an exclusive licensing agreement with Translational Sciences, Inc., a clinical stage biopharmaceutical company, to develop and commercialise its novel thrombus (blood clot) dissolving agent, TS23, which is currently undergoing phase I clinical trials.

Based on this agreement, Daiichi Sankyo will pay Translational Sciences unspecified fees, milestones and royalties for exclusive rights to globally develop and commercialise TS23.

This agreement with Translational Sciences, Inc. for Daiichi Sankyo to develop and commercialise this unique thrombus dissolving agent, TS23, is in line with the Daiichi Sankyo R&D strategy to expand its portfolio in the prevention and treatment of thrombosis.

Dr. Guy Reed, CSO/CEO of Translational Sciences said, “Daiichi Sankyo recognised the great potential of this novel therapy. We believe they have the expertise and resources to fully develop it for the millions of patients each year who suffer cardiovascular disease and stroke. We are enormously grateful to the National Institutes of Health who provided crucial support to translate this research into therapy.”